KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jun 13, 2025 >>  ABB India 5996.85  [ -0.59% ]  ACC 1847.35  [ -1.00% ]  Ambuja Cements 543.25  [ -0.92% ]  Asian Paints Ltd. 2215.3  [ -0.12% ]  Axis Bank Ltd. 1205.95  [ -0.56% ]  Bajaj Auto 8463.8  [ -1.20% ]  Bank of Baroda 239.1  [ -0.83% ]  Bharti Airtel 1842.15  [ -0.10% ]  Bharat Heavy Ele 253.55  [ -0.14% ]  Bharat Petroleum 312.65  [ -1.90% ]  Britannia Ind. 5569.45  [ -0.01% ]  Cipla 1505.4  [ 0.22% ]  Coal India 391.35  [ -0.32% ]  Colgate Palm. 2373.75  [ -1.26% ]  Dabur India 466.65  [ -1.31% ]  DLF Ltd. 851.8  [ 0.48% ]  Dr. Reddy's Labs 1361.45  [ -0.12% ]  GAIL (India) 191.4  [ -0.42% ]  Grasim Inds. 2664.95  [ -0.87% ]  HCL Technologies 1694.85  [ -0.43% ]  HDFC Bank 1917.25  [ -1.27% ]  Hero MotoCorp 4330.55  [ -0.70% ]  Hindustan Unilever L 2319.1  [ -0.65% ]  Hindalco Indus. 641.55  [ -1.45% ]  ICICI Bank 1416.2  [ -0.64% ]  Indian Hotels Co 733.25  [ -1.46% ]  IndusInd Bank 816.55  [ -1.59% ]  Infosys L 1601.55  [ -0.36% ]  ITC Ltd. 413.9  [ -1.67% ]  Jindal St & Pwr 920.7  [ -1.99% ]  Kotak Mahindra Bank 2110.8  [ -0.71% ]  L&T 3588.25  [ -0.43% ]  Lupin Ltd. 2000.35  [ -1.08% ]  Mahi. & Mahi 3006  [ -0.39% ]  Maruti Suzuki India 12411.45  [ 0.24% ]  MTNL 52.08  [ -4.32% ]  Nestle India 2376.5  [ -0.45% ]  NIIT Ltd. 134.1  [ -1.58% ]  NMDC Ltd. 70.38  [ -2.80% ]  NTPC 332  [ -0.43% ]  ONGC 251.4  [ 1.45% ]  Punj. NationlBak 106.55  [ -1.39% ]  Power Grid Corpo 285.7  [ -1.07% ]  Reliance Inds. 1427.65  [ -0.83% ]  SBI 792.4  [ -1.64% ]  Vedanta 457.8  [ -0.51% ]  Shipping Corpn. 226.5  [ 9.74% ]  Sun Pharma. 1688.7  [ 0.10% ]  Tata Chemicals 925.2  [ -0.77% ]  Tata Consumer Produc 1078.45  [ -0.52% ]  Tata Motors 712.05  [ -0.41% ]  Tata Steel 152.2  [ -0.43% ]  Tata Power Co. 397.35  [ -1.06% ]  Tata Consultancy 3447.1  [ 0.38% ]  Tech Mahindra 1658.95  [ 0.93% ]  UltraTech Cement 11220.7  [ -0.83% ]  United Spirits 1452.15  [ -2.22% ]  Wipro 260.2  [ 0.29% ]  Zee Entertainment En 137.35  [ 2.08% ]  
  • Share Prices
  • Tools
  • News
  • Company Details
  • Financial Data
  • Results
  • Key Financial Ratios
  • Reports
  • Corporate Announcements
  • Equity History

    • Company Information

    Indian Indices
    • Loading....

    Global Indices
    • Loading....

    Forex
    • Loading....

    SYNGENE INTERNATIONAL LTD.

    13 June 2025 | 12:00

    Industry >> Medical Research Services

    Select Another Company

    ISIN No INE398R01022 BSE Code / NSE Code 539268 / SYNGENE Book Value (Rs.) 109.10 Face Value 10.00
    Bookclosure 27/06/2025 52Week High 961 EPS 12.31 P/E 53.04
    Market Cap. 26315.97 Cr. 52Week Low 600 P/BV / Div Yield (%) 5.99 / 0.19 Market Lot 1.00
    Security Type Other

    History of Company

    The company history sections lists out major chronological events that happened to the company.
    The Company was incorporated as Syngene International Private Limited on November 18, 1993 at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. Pursuant to a special resolution of the shareholders dated March 26, 2007, the Company was converted into a public limited company and the name of the Company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19, 2007. the Company was promoted by Kiran Mazumdar Shaw, a promoter of Biocon. On March 30, 2002, 99.9 percent of the Equity Shares of the Company were transferred to Biocon and as a result, the Company became the subsidiary of Biocon. Biocon has since been the Promoter of the Company.The details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India.

    Major events and milestones of the Company :

    1994

    -Initiated operations as a CRO with services in chemistry and biology

    1998

    -Granted 100% Export Oriented Unit (EOU) status by the Government of India

    1999

    -First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.

    2000

    -CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies

    2001

    -Forayed into chemical development with a dedicated manufacturing facility

    2003

    -Moved to Biocon Park, a 90 acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.

    2007

    -Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D centre

    -Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.

    -Crossed an annual turnover of over `1,000 million in Financial Year 2007

    2009

    -Dupont Crop Protection and the Company extended a partnership for R&D services

    -Expansion of manufacturing services with a new plant which is cGMP compliant

    -Initiated operations in safety assessment and large molecules development services

    2010

    -Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA

    -Initiated operations in formulation development

    2011

    -Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer

    2012

    -Abbott and the Company collaborated to establish Abbott's nutrition research and development centre in India and the second R&D centre

    -Certification of the clinical facilities by ANVISA

    -Acquired 100% stake in Clinigene International Limited from Biocon

    2013

    -Crossed an annual turnover of over `5,000 million in Financial Year 2013

    -Baxter International Inc. collaborated with the Company to establish the `Baxter Global Research Center', the third dedicated R&D centre

    -Acceptance of the control testing laboratory by the Department of Health & Human Services, FDA

    2014

    -Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D centre till 2020

    -Acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA

    -Established a 75,000 sq.ft centre to provide stability and analytical services

    2015 -CIL was amalgamated with the Company Awards, Recognitions and Accreditations :

    2009 - Bangalore Bio, Bio Excellence Award - Biotech Services Sector - Best BioServices company of the year by Biospectrum

    2012 - ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - AAALAC accreditation for conforming to the "Guide for the Care and Use of Laboratory Animals and the Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines"

    2013 - Bioservices - ABLE Tenth Anniversary Award - Outstanding contribution to Bioservices - Diamond sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology

    2014 - ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - Silver EDGE Award - EHS best practices award by CII - SAP Ace Award for special recognition for complex SAP implementation - Level I Laboratory certification issued by the NGSP to Clinigene International Limited

    2015 - Accreditation by the College of American Pathologists in relation to their laboratory accreditation program - Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector - ISO 15189:2007 in the field of medical testing

    2017 -Herbalife Nutrition Partners with Syngene to Establish Nutrition Research and Development Lab in India. -"Syngene International Announces Broadening of Research Collaboration with Amgen Inc." expands Dedicated R&D Center. -"Bristol-Myers Squibb and Syngene International Expand Ongoing Research Collaboration.".

    2018 -Syngene signs R&D agreement with GSK. -"Syngene International Expands Collaboration with Baxter". -Best Bioprocessing Excellence Award 2018. -Bio-Excellence Award 2018.

    2019 -"Syngene International wins CMO Leadership Awards presented by Life Science Leader Magazine". -India Pharma Award 2019. -Pharma and Chemical Manufacturing Category by National Safety Council of India (NSCI). Leadership Awards.

    2020 -Syngene ties up with HiMedia Laboratories to manufacture ELISA test kits for COVID-19. -Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing. -Syngene and PharmAust collaborate to manufacture GMP-grade Monepantel for Human Clinical Trials. -Bioprocessing Excellence Award 2020.

    2021 -Syngene receives India Pharma Awards 2021. -Syngene Ranked As One Of The Top 100 Indian Wealth Creators For 2021. -Syngene International extends long term research collaboration with Bristol Myers Squibb until 2030. -Syngene through Biocon Foundation partners with NIMHANS for BHUMI.

    2022 -Syngene International takes top honors at CMO Leadership Awards 2022 for contract manufacturing. -Syngene signs 10-year biologics manufacturing agreement with leading animal health company. -Syngene and the Research and Innovation Circle of Hyderabad (RICH) launch scholarship program for women studying STEM subjects.

    2023

    -Winner of India's Best Managed Companies 2023 programme -Supply Chain Champion Award, 2023 -Best Overall Sustainable Performance (Pharmaceutical) 2023 -Biopharma Excellence Award (India Edition) 2023 -Panbela announces issuance of new patent in Australia. Patent is for claims of a novel process for the production of SBP-101

    2024 -Syngene received Pharmaceutical Technology Excellence Awards 2024. -Syngene received Asia Pacific Biologics CMO Excellence Awards 2024. -Syngene awarded CDMO Leadership Awards 2024. -Syngene secures silver rating in EcoVadis sustainability index, ranking in top 15% of assessed companies. -Syngene launches platform for rapid, enhanced protein production. -Syngene International named as one of `India's Best Managed Companies by Deloitte India.

    Way2Wealth Brokers Private Limited - CIN U67120KA2000PTC027628 Stock Broking: SEBI Regn No.: INZ000178638 | Exchange Membership ID: NSE: 11502, BSE: 3117, MSEI:51000, MCX: 56730 Depository Participant: SEBI Regn No. IN-DP-472-2020 | CDSL ID: 12062900 & 12031500, NSDL ID: IN303077 PMS: SEBI Regn No.INP000000829 | Register with AMFI ARN: 77558 (Date of Initial registration - 8th Dec 2009, Date of expiry - 24th Jan 2027) | PFRDA: POP226012019

    Way2Wealth Commodities Private Limited - CIN U51229KA2006PTC039880 Stock Broking: SEBI Regn No.: INZ000049130 | Exchange Membership ID: NCDEX : 00908

    Copyrights @ 2014 © Way2Wealth Brokers Pvt. Ltd. All rights reserved

    Designed, developed and content provided by  Dion

    Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.